Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Paroxysmal nocturnal hemoglobinuria affects approximately 1-1.5 per million population in Western countries. Median survival before complement inhibitor…
Sweden's Sobi will pay $250 million up front and up to $915 million in milestones for the ex-US rights to Apellis Pharmaceuticals' rare-disease treatment…
The U.S. Food and Drug Administration today approved Empaveli (pegcetacoplan) injection to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).…
Source summaries from our enrichment pipeline; follow links for originals.
All 16 sources with sentiment breakdown →
Apellis and Sobi announced a collaboration on 27 October 2020 granting Sobi exclusive ex-US development and commercialization rights to systemic pegcetacoplan for PNH and other complement-mediated diseases. Apellis received $250M upfront with eligibility for up to $915M in development, regulatory and sales milestones plus tiered double-digit royalties; Apellis retained US rights and global ophthalmology rights. The deal closed 8 December 2020. The partnership has since been validated and materially expanded: the European Commission approved Aspaveli (pegcetacoplan) for PNH on 15 December 2021 and for C3 glomerulopathy (C3G) and primary IC-MPGN in patients aged 12+ on 16 January 2026 (the first approved therapy for primary IC-MPGN), opening a second ex-US franchise for Sobi. On 1 July 2025 Sobi deepened its economic stake via a royalty purchase agreement, paying Apellis $275M upfront plus up to $25M in milestones (the $25M was triggered by the January 2026 EU C3G/IC-MPGN approval) to acquire 90% of Apellis' ex-US Aspaveli royalties, with royalties reverting toward the original license terms once defined commercial caps are met.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. (this deal) | 2020 | $1.0B | — |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. | 2025 | $1.5B | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
← Browse all deals · How we score deals
More: 2020 deals · Swedish Orphan Biovitrum AB deals · Immunology deals